home / conference / esmo-immuno-oncology-congress Content TypeNeoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC By Caroline Seymour January 6th 2024 Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following ...